Immunohistochemical Markers in the Assessment of Tumor Response

Abstract

The examination of the possibility of using immunohistochemical and molecular (NCRT) and prognostic factors of the disease state. The study included 21 patients with locally advanced gastric cancer. All patients underwent the NCRT followed by gastrectomy D2. We analyzed the expression of HER2 / neu marker, Ki-67, p53, Cyklin D1, E-cadherin in biopsy (before therapy) and the operating material (after chemoradiotherapy and the treatment gap). We have found statistically significant decrease in the expression of Ki-67 markers and Cyklin D1, a trend towards to a decrease of p53 expression after the NCRT. The dynamics of expression of immunohistochemical markers examination is a promising approach in search for predictors of NCRT effectiveness for patients with locally advanced gastric cancer.


Keywords: neoadjuvant chemoradiotherapy, immunohistochemical markers, molecular genetic markers, therapeutic pathomorphism, gastric cancer.

References
[1] World Cancer Report 2014: - Lyon, France: International Agency for Research on Cancer, P. 16, 2014.


[2] A. Tannapfel, S. Nüßlein, R. Fietkau, Apoptosis, proliferation, Bax, Bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer, Int. J. Radiat. Oncol., Vol. 41, № 3., P. 585–591, 1998.


[3] S.A. Мozerov, Y.A. Komin, E.S. Mozerova, O.V.Krasovitova, Morphological and clinical changes of gastric cancer after neoadjuvant chemoradiotherapy (review of literature), International journal of applied and fundamental research, vol. 6, № 1., pp. 59–64, 2016.